[Cicletanine tolerance in hypertensive patients with metabolic disorders].
In this double-blind trial, the clinical and biochemical side-effects of cicletanine 150-200 mg/day were compared with those of indapamide 2.5 mg/day in a population of hypertensive with such metabolic disorders as diabetes mellitus, obesity, hyperlipidaemia or hyperuricaemia. Sixteen patients received cicletanine and 15 indapamide; 2 patients in the indapamide group were excluded, one for undesirable effect, the other for unexpected effect. The two treatments did not produce any significant change in natremia, glycaemia, uricemia, creatininemia or blood lipid level. Kalemia remained stable under cicletanine but was significantly reduced under indapamide, requiring supplementation with potassium salts in 5 patients. Both cicletanine and indapamide proved to be effective as antihypertensive drugs, although blood pressure levels at inclusion were different in each of the two groups.
Passa
P
P
Service d'endocrinologie, hôpital Saint-Louis, Paris.
D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004232:Diuretics / Q000494:pharmacology* / Q000627:therapeutic use; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D007190:Indapamide / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008659:Metabolic Diseases / Q000097:blood* / Q000150:complications; D011725:Pyridines; D016032:Randomized Controlled Trials as Topic
D000959:Antihypertensive Agents; D004232:Diuretics; D011725:Pyridines; C038068:cicletanine; D007190:Indapamide
Etude de la tolérance du ciclétanine chez des patients hypertendus présentant des troubles métaboliques.